Latest News and Press Releases
Want to stay updated on the latest news?
-
Amryt Announces 22% growth in FY 2021 Revenues to $222.5M Issuing FY 2022 revenue guidance of $260M - $270M, representing 17%-21% YoY growth Cash of $113.0M at December 31, 2021 Board approves...
-
Amryt Announces Successful Bioavailability Study for Mycapssa® (octreotide capsules) Data supports a planned Phase 3 study in the treatment of carcinoid symptoms associated with Neuroendocrine Tumors...
-
Results of General Meeting Share-Repurchase Program Form of Contract and Counterparties Approved DUBLIN, Ireland, and Boston MA, March 3, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage...
-
Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA DUBLIN, Ireland, and Boston, MA, February 28, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company...
-
Amryt Supports Rare Disease Day 2022 DUBLIN, Ireland, and Boston MA, February 25, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing...
-
Amryt to Report FY and Q4 2021 Results on March 9, 2022 DUBLIN, Ireland, and Boston MA, February 23, 2022, Amryt (Nasdaq: AMYT) a global, commercial-stage biopharmaceutical company dedicated to...
-
Amryt Completes $125 Million Non-Dilutive Debt Refinancing New Facilities Will Significantly Reduce Amryt’s Interest Expense and Cost of Capital and Extend Term Debt Maturity Through 2027 Further...
-
Notice of General Meeting Amryt seeking shareholder approval for share buybacks and routine matters DUBLIN, Ireland, and Boston MA, February 1, 2022, Amryt Pharma plc (Nasdaq: AMYT), a global,...
-
Amryt Announces Oleogel-S10 EMA Regulatory Update Ad-Hoc Expert Group to provide independent EB specific expertise and advice DUBLIN, Ireland, and Boston MA, January 28, 2022 Amryt (Nasdaq:...
-
Amryt Announces New Patents for Oleogel-S10 DUBLIN, Ireland, and Boston MA, January 18, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring,...